<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="154428">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01089569</url>
  </required_header>
  <id_info>
    <org_study_id>03951-10-C</org_study_id>
    <nct_id>NCT01089569</nct_id>
  </id_info>
  <brief_title>Continuous Glucose Monitoring Evaluation of Exenatide Twice Daily Versus Insulin Glargine</brief_title>
  <official_title>Evaluation of Insulin Glargine and Exenatide: A Randomized Clinical Trial With Continuous Glucose Monitoring and Ambulatory Glucose Profile Analysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>HealthPartners Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>International Diabetes Center at Park Nicollet</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>HealthPartners Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to compare the effect on 24-hour blood glucose
      patterns, HbA1c, and weight management when adding insulin glargine, or exenatide, or a
      combination of insulin glargine and exenatide to metformin.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2010</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Continuous Glucose Monitoring</measure>
    <time_frame>40 weeks</time_frame>
    <description>Employ CGM with AGP analysis to characterize the diurnal patterns produced by oral medications (metformin) used in the treatment of type 2 diabetes.
Employ CGM to measure the effect of exenatide, insulin glargine and exenatide plus insulin glargine in terms of underlying physiological defects and alter medications in a manner that improves- i. Glucose exposure (area under the diurnal median curve) ii. Glucose variability (inter-quartile range) iii. Glucose stability (hourly change in the median curve iv. Incidence of hypoglycemia (degree, duration, frequency)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Continuous Glucose Monitoring and Lab Tests</measure>
    <time_frame>40 weeks</time_frame>
    <description>Measure the changes in HbA1C attributable to exenatide, insulin glargine and their combination Measure the changes in weight attributable to exenatide, insulin glargine and their combinations.
Employ CGM with AGP analysis to determine if there is an incremental benefit for subjects who do not reach target to add exenatide to insulin glargine or insulin glargine to exenatide in patients taking metformin.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>5 mcg BID for 1 month increasing to 10 mcg BID for the remainder of the study</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exenatide + Insulin Glargine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>refer to Arm detail</description>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_label>Exenatide + Insulin Glargine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>refer to Arm detail</description>
    <arm_group_label>Insulin Glargine</arm_group_label>
    <arm_group_label>Exenatide + Insulin Glargine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥18 and ≤75 years of age

          -  Clinical diagnosis of type 2 diabetes

          -  Diabetes duration ≥ 1 year

          -  HbA1c ≥7.0%

          -  Currently treated with metformin (HbA1c ≤9%) or metformin/sulfonylurea (SU) (HbA1c
             ≤8%)or SU alone (HbA1c ≤8%)

        Exclusion Criteria:

          -  Previously treated with insulin or incretin-based therapy

          -  Treated with a thiazolidinedione within past 6 weeks

          -  Taken oral or injected prednisone or cortisone medications in the previous 30 days

          -  Any pancreatic disease or at high risk of pancreatitis (history of alcohol abuse,
             active gallbladder disease)

          -  Serum creatinine &gt;1.4mg/dL (women) or &gt;1.5 mg/dL (men)

          -  eGFR &lt;30 ml/min (using MDRD equation

          -  ALT&gt;2xULN

          -  Presence of any severe medical or psychological condition or chronic
             conditions/infections that in the opinion of the Investigator would compromise he
             subject's safety or successful participation in the study

          -  Currently pregnant or planning pregnancy during the study period

          -  Unable to follow the study protocol

          -  Unable to speak, read and write in English

          -  Uncontrolled hyperglycemia with HbA1c &gt; 9% on metformin or &gt;8% on SU or metformin/SU
             combination or ketonuria requiring immediate insulin therapy

          -  At the investigator's discretion for other medical or psychological reasons
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard M Bergenstal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Roger S Mazze, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elinor S Strock, APRN</last_name>
    <role>Principal Investigator</role>
    <affiliation>International Diabetes Center at Park Nicollet</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>International Diabetes Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55416</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Mazze RS, Strock E, Wesley D, Borgman S, Morgan B, Bergenstal R, Cuddihy R. Characterizing glucose exposure for individuals with normal glucose tolerance using continuous glucose monitoring and ambulatory glucose profile analysis. Diabetes Technol Ther. 2008 Jun;10(3):149-59. doi: 10.1089/dia.2007.0293.</citation>
    <PMID>18473688</PMID>
  </reference>
  <reference>
    <citation>Mazze R, Strock E, Morgan B, Wesley D, Bergenstal R, Cuddihy R. Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. Endocr Pract. 2009 May-Jun;15(4):326-34. doi: 10.4158/EP09046.ORR.</citation>
    <PMID>19454385</PMID>
  </reference>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>November 30, 2015</lastchanged_date>
  <firstreceived_date>March 17, 2010</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <keyword>exenatide</keyword>
  <keyword>insulin glargine</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Exenatide</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
